Product Name :
(R)-2-HG —a-KG-dependent dioxygenases inhibitor
Description:
Mutations in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R)-enantiomer of 2- hydroxyglutarate [(R)-2-HG]. Elucidation of the role of IDH mutations and (R)-2-HG in leukemogenesis has been hampered by a lack of appropriate cell-based models. It has been recently reported that a canonical IDH1 mutant, IDH1 R132H, promoted cytokine independence and blocks differentiation in hematopoietic cells. These effects can be recapitulated by (R)-2-HG, but not (S)-2-HG, despite the fact that (S)-2-HG more potently inhibits enzymes previously linked to the pathogenesis of IDH mutant tumors, such as the 5′- methylcytosine hydroxylase TET2. This paradox is perhaps due to the ability of (S)-2-HG, but not (R)-2-HG, to inhibit the EglN prolyl hydroxylases. 2-HG has also been shown to inhibit the activity of multiple other a- KG-dependent dioxygenases, including the JmjC domain-containing histone demethylases (KDMs).
CAS:
103404-90-6
Molecular Weight:
192.08
Formula:
C5H6Na2O5
Chemical Name:
sodium (R)-2-hydroxypentanedioate
Smiles :
[Na+].[Na+].[O-]C(=O)CC[C@@H](O)C([O-])=O
InChiKey:
DZHFTEDSQFPDPP-HWYNEVGZSA-L
InChi :
InChI=1S/C5H8O5.2Na/c6-3(5(9)10)1-2-4(7)8;;/h3,6H,1-2H2,(H,7,8)(H,9,10);;/q;2*+1/p-2/t3-;;/m1../s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition :
Powder: 4oC for 1 year, -20oC for 3 years. DMSO: 4oC for 3 month.
Shelf Life:
≥36 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Mutations in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R)-enantiomer of 2- hydroxyglutarate [(R)-2-HG].{{β-Endorphin, human} site|{β-Endorphin, human} Agonist|{β-Endorphin, human} TGF-beta/Smad|{β-Endorphin, human} Biological Activity|{β-Endorphin, human} Data Sheet|{β-Endorphin, human} custom synthesis} Elucidation of the role of IDH mutations and (R)-2-HG in leukemogenesis has been hampered by a lack of appropriate cell-based models. It has been recently reported that a canonical IDH1 mutant, IDH1 R132H, promoted cytokine independence and blocks differentiation in hematopoietic cells. These effects can be recapitulated by (R)-2-HG, but not (S)-2-HG, despite the fact that (S)-2-HG more potently inhibits enzymes previously linked to the pathogenesis of IDH mutant tumors, such as the 5′- methylcytosine hydroxylase TET2. This paradox is perhaps due to the ability of (S)-2-HG, but not (R)-2-HG, to inhibit the EglN prolyl hydroxylases. 2-HG has also been shown to inhibit the activity of multiple other a- KG-dependent dioxygenases, including the JmjC domain-containing histone demethylases (KDMs).|Product information|CAS Number: 103404-90-6|Molecular Weight: 192.08|Formula: C5H6Na2O5|Synonym:|D-alpha-Hydroxyglutaric acid disodium|D-2-Hydroxypentanedioic acid disodium salt|Disodium (R)-2-Hydroxyglutarate|2R-hydroxy-pentanedioic acid, disodium salt|D-alpha-Hydroxyglutaric acid disodium salt|Pentanedioic acid, 2-hydroxy-, disodium salt, (R)-|D-2-Hydroxypentanedioic acid-2Na+|disodium (2R)-2-hydroxypentanedioate|r-2-hydroxyglutaric acid disodium salt|D-A-HYDROXYGLUTARIC ACID DISODIUM|MDK4906|[R, (+)]-2-Hydroxyglutaric acid disodium salt|Chemical Name: sodium (R)-2-hydroxypentanedioate|Smiles: [Na+].{{Pembrolizumab (anti-PD-1)} MedChemExpress|{Pembrolizumab (anti-PD-1)} Immunology/Inflammation|{Pembrolizumab (anti-PD-1)} Epigenetics|{Pembrolizumab (anti-PD-1)} Purity & Documentation|{Pembrolizumab (anti-PD-1)} Formula|{Pembrolizumab (anti-PD-1)} custom synthesis} [Na+].PMID:23618405 [O-]C(=O)CC[C@@H](O)C([O-])=O|InChiKey: DZHFTEDSQFPDPP-HWYNEVGZSA-L|InChi: InChI=1S/C5H8O5.2Na/c6-3(5(9)10)1-2-4(7)8;;/h3,6H,1-2H2,(H,7,8)(H,9,10);;/q;2*+1/p-2/t3-;;/m1../s1|Technical Data|Appearance: Solid powder|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Water up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.|Storage Condition: Powder: 4oC for 1 year, -20oC for 3 years. DMSO: 4oC for 3 month.|Shelf Life: ≥36 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|(R)-2-HG was used at 100-250 μM final concentration in vitro and in cellular assays.|References:|Losman JA, et al. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. (2013) Science. 339(6127):1621-5.Ye D, et al. R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis. (2013) Cancer Cell. 23(3):274-6.Products are for research use only. Not for human use.|Documents||